59.86 -0.23 (-0.38%)
After hours: 4:00PM EST
|Bid||60.02 x 800|
|Ask||60.15 x 900|
|Day's Range||59.90 - 60.80|
|52 Week Range||29.01 - 75.72|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||27.85|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.75|
Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced its participation in two upcoming international conferences – the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany, and the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting on November 21-22 in Vienna, Austria. “We are excited to showcase our deep and innovative portfolio of osteoarthritis pain management and joint preservation and restoration therapies before the international medical community,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics.
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Anika Therapeutics, Inc. (NASDAQ:ANIK). Anika Therapeutics, Inc. (NASDAQ:ANIK) was in […]
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform, today announced plans to showcase its osteoarthritis pain management and joint preservation and restoration regenerative therapies at the 2019 Fortius International Sports Injury Conference (FISIC). The 2019 FISIC is being held November 6-7, 2019 in London, England and will focus on the latest practices in orthopedics and sports injury medicine for orthopaedic surgeons, sports physicians, radiologists, physiotherapists, and other sports and exercise professionals.
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.